Loading...
Loading...
BBLG| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 0.0K |
| Operating Expense | 951.0K |
| Operating I/L | -951.0K |
| Other Income/Expense | 10.0K |
| Interest Income | 20.0K |
| Pretax | -941.0K |
| Income Tax Expense | 0.0K |
| Net Income/Loss | -941.0K |
Bone Biologics Corporation is a medical device company specializing in bone regeneration for spinal fusion using the recombinant human protein NELL-1/DBX. Their NELL-1/DBX Fusion Device targets specific control over bone regeneration, offering enhanced outcomes in spinal, orthopedic, plastic reconstruction, neurosurgery, and sports medicine. The company's revenue is generated through the development and commercialization of NELL-1/DBX for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. They have a license agreement with the UCLA Technology Development Group, positioning them as a leader in the field of bone regeneration for surgical specialties.
